We are live on ! Find out more
BBLG

Bone Biologics
BBLG

2 hedge funds and large institutions have $43K invested in Bone Biologics in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

33% less funds holding

Funds holding: 3 → 2 (-1)

36% less capital invested

Capital invested by funds: $67K → $43K (-$24K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$1.87K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$11K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$35K – – –
TRCT
2
Tower Research Capital (TRC)
New York
$8K +$1.87K +1 +25%
UBS Group
3
UBS Group
Switzerland
– -$11K -5 Closed

BBLG Hedge Fund Activity: Q3 2022 in Review

2 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q3 2022, worth a combined $43K — down 36% from $67K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of BBLG and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $1.87K. The largest seller was UBS Group, exiting entirely with an estimated $11K sold.

  • 2 institutional investors held Bone Biologics (BBLG) as of Q3 2022, down from 3 in Q2 2022.
  • Funds reported $43K of Bone Biologics stock for Q3 2022, down 36% quarter-over-quarter.
  • 0 funds opened new Bone Biologics positions in Q3 2022 and 1 closed out, a net change of -1 holder.
  • The largest Bone Biologics buyer in Q3 2022 was Tower Research Capital (TRC), an estimated $1.87K added.
  • The largest Bone Biologics seller in Q3 2022 was UBS Group, an estimated $11K sold.

Based on aggregated 13F filings for Q3 2022.